Michael Andrew Postow
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 188
- Cancer Immunotherapy and Biomarkers 158
- CAR-T cell therapy research 92
- Cutaneous Melanoma Detection and Management 26
- Immunology 82
- Immunotherapy and Immune Responses 63
- Immune Cell Function and Interaction 16
- Co-authors
- Jedd D. Wolchok (80 shared papers)Margaret K. Callahan (46 shared papers)Matthew David Hellmann (11 shared papers)Robert Sidlow (2 shared papers)Claire Frances Friedman (8 shared papers)David B. Page (5 shared papers)Chrisann Kyi (6 shared papers)Mario E. Lacouture (8 shared papers)
- Journals
- Journal for ImmunoTherapy of Cancer (24 papers)Journal of Clinical Oncology (17 papers)Clinical Cancer Research (15 papers)Annals of Oncology (12 papers)The Oncologist (11 papers)
- Partner nations
- United StatesItalyFrance
In The Last Decade
Michael Andrew Postow
255 papers receiving 56.5k citations
Michael Andrew Postow's Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 38.8k
- Immunology 18.7k
- Cancer Research 4.1k
- Pulmonary and Respiratory Medicine 8.4k
- Genetics 2.4k
Countries citing papers authored by Michael Andrew Postow
This map shows the geographic impact of Michael Andrew Postow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Andrew Postow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Andrew Postow more than expected).
Fields of papers citing papers by Michael Andrew Postow
This network shows the impact of papers produced by Michael Andrew Postow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Andrew Postow. The network helps show where Michael Andrew Postow may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Andrew Postow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 264 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Hit paper breakdown → | 2015 | 6916 |
| 2 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2017 | 4597 |
| 3 | Immune-Related Adverse Events Associated with Immune Checkpoint Blockade Hit paper breakdown → | 2018 | 3780 |
| 4 | Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma Hit paper breakdown → | 2014 | 3649 |
| 5 | Nivolumab plus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2013 | 3591 |
| 6 | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Hit paper breakdown → | 2015 | 2365 |
| 7 | Immune Checkpoint Blockade in Cancer Therapy Hit paper breakdown → | 2015 | 2289 |
| 8 | OncoKB: A Precision Oncology Knowledge Base Hit paper breakdown → | 2017 | 1972 |
| 9 | Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma Hit paper breakdown → | 2012 | 1773 |
| 10 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Hit paper breakdown → | 2014 | 1540 |
| 11 | T-cell invigoration to tumour burden ratio associated with anti-PD-1 response Hit paper breakdown → | 2017 | 1361 |
| 12 | Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies Hit paper breakdown → | 2015 | 1299 |
| 13 | Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain Hit paper breakdown → | 2018 | 1038 |
| 14 | Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy Hit paper breakdown → | 2016 | 938 |
| 15 | Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center Hit paper breakdown → | 2015 | 905 |
| 16 | Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Hit paper breakdown → | 2016 | 811 |
| 17 | Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors Hit paper breakdown → | 2016 | 685 |
| 18 | Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab Hit paper breakdown → | 2016 | 497 |
| 19 | MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma Hit paper breakdown → | 2018 | 493 |
| 20 | 2016 | 475 |
About Michael Andrew Postow
Michael Andrew Postow is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 264 papers that have together received 57.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (158 papers), CAR-T cell therapy research (92 papers), Immunotherapy and Immune Responses (63 papers), Melanoma and MAPK Pathways (31 papers), Cutaneous Melanoma Detection and Management (26 papers), Brain Metastases and Treatment (17 papers), Immune Cell Function and Interaction (16 papers) and Cancer Genomics and Diagnostics (14 papers). The work is most often cited by research in Oncology (38.8k citations), Immunology (18.7k citations), Cancer Research (4.1k citations), Pulmonary and Respiratory Medicine (8.4k citations) and Genetics (2.4k citations). Michael Andrew Postow has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Jedd D. Wolchok, Margaret K. Callahan, Matthew David Hellmann, Robert Sidlow, Claire Frances Friedman, David B. Page, Chrisann Kyi, Mario E. Lacouture, Tracy Ann Proverbs-Singh and Richard D. Carvajal. Their work appears in journals such as Journal for ImmunoTherapy of Cancer, Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.